SCHEMBL1277412

SCHEMBL1277412

C/C(=C\c1ccccc1-c1ccc(CO)cc1)C(=O)NC(=N)N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 3/20 0.37
BAZ2B Q9UIF8 1/20 0.36
BAZ2A Q9UIF9 1/20 0.36
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
LTB4R2 Q9NPC1 2/20 0.34
LTB4R Q15722 1/20 0.34
APEX1 P27695 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PRSS1 P07477 4/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
TMPRSS15 P98073 2/20 0.32
HDAC2 Q92769 1/20 0.32
PDCD1 Q15116 4/20 0.31
CD274 Q9NZQ7 4/20 0.31
BACE1 P56817 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277160 0.88 SMN1; SMN2 (0.41) F10NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL1277277 0.88 BACE1 (0.40) F10APEX1PRSS1BACE1
SCHEMBL1277875 0.86 F10 (0.44) F10PRSS1PRSS2PRSS3TMPRSS15
SCHEMBL1277154 0.86 SLC6A4 (0.41) F10APEX1NPC1RAB9ASMN1; SMN2
SCHEMBL1277454 0.86 MKNK1 (0.40) F10NPC1RAB9ASMN1; SMN2PRSS1
SCHEMBL1277231 0.85 F10 (0.39) F10NPC1RAB9ASMN1; SMN2PRSS1
SCHEMBL1277466 0.84 FGFR1 (0.41) F10NPC1RAB9ASMN1; SMN2HDAC2
SCHEMBL1708738 0.84 F10 (0.36) F10CA1CA2APEX1
SCHEMBL1277136 0.84 FFAR1 (0.39) NPC1ALDH1A1RAB9ASMN1; SMN2PRSS1
SCHEMBL1277453 0.83 PTPN1 (0.43) F10CA1CA2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885BAZ2B 1648/4885BAZ2A 1311/4885
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885BAZ2B 1648/4885BAZ2A 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.